The wait is over: AbbVie’s Rinvoq chalks up FDA win with favorable atopic dermatitis label Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial CMS sets COVID-19 vaccination deadlines for healthcare workers in 24 more states The top 10 biopharma M&A deals in 2021 The top 10 medtech M&A deals of 2021 Sema4 signals $623M acquisition of genetic testing provider GeneDx Fierce JPM Week: 5 industry execs discuss pandemic supply chain issues, solutions Fierce JPM Week: Bayer's new R&D chief wants to push past Aspirin legacy with innovation Fierce JPM Week: Pharma reflects on pandemic's 'aha! moments,' which spurred new drive for clinical trial diversity Microsoft, Cleveland Clinic and Providence join coalition to innovate AI in healthcare Philips taps Cydar to add AI, 3D mapping to mobile X-ray platform As TEFCA goes live, HHS hits major interoperability milestone Inside the Catalent FDA citation said to trigger Novo Nordisk's Wegovy supply hiccup Schrödinger picks up protein crystallographer XTAL BioStructures Featured Story | By Angus Liu AbbVie can breathe a sigh of relief: Rinvoq, the Illinois pharma’s Humira successor, has emerged from an FDA safety probe with a relatively favorable label in the all-important atopic dermatitis indication. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Ionis Pharmaceuticals-partnered tominersen looked to be down and out when Roche revealed the extent of its phase 3 failure in patients with Huntington's disease last year. But an encouraging signal in the wreckage of the clinical trial has offered a reprieve—and persuaded Roche to wind back to phase 2 to see whether the sign of efficacy holds up to rigorous study. read more By Dave Muoio Provider organizations in 49 states will need to ensure staff begin vaccinating in the coming weeks or face enforcement penalties, CMS said Friday. Texas is the country's final holdout state due to a preliminary injunction still in place. read more By Phil Taylor Biopharma merger and acquisition (M&A) activity was subdued in 2021 and would have approached a record low for recent years if not for a flurry of deals in the last quarter. read more By Conor Hale,Andrea Park Many of 2021's medtech acquisitions were fueled by pandemic windfalls, driven by a year of roller-coaster demand for coronavirus diagnostics and supplies. read more By Andrea Park Fresh off a SPAC deal that brought in $500 million in cash proceeds, Sema4 is putting those earnings to good use, with a buyout bid for genomic testing and analysis company GeneDx. read more By Kevin Dunleavy While drug supply chains generally held up during the pandemic, it was no easy feat. COVID-19 showed the industry just how vulnerable the supply chain could become, and it spawned new efforts to regionalize manufacturing and double down on automation. In a panel discussion during Fierce JPM Week, five industry executives talked about the challenges and solutions. read more By Kyle LaHucik As head of global R&D for Bayer, Christian Rommel is attempting to chart a reinvention of research and development at the storied Big Pharma. Recent acquisitions, leadership additions and developments in technology will all have to work in his favor to bring Bayer into the next stage. read more By Annalee Armstrong The pharmaceutical industry picked up digital clinical trial tools during the pandemic that can also be used to tackle the lack of diversity in research. So that’s it. The issue is solved. Not so fast, as a panel of experts attested during a session on new paths to trial diversity at Fierce JPM Week, which kicks off Tuesday. read more By Rebecca Torrence Microsoft has formed a coalition to build and track new AI innovations with some big names in healthcare, including Cleveland Clinic, Intermountain Healthcare, Providence and more. read more By Andrea Park Amid its continued struggles with the far-ranging recall of many of its CPAP and BiPAP machines and other respiratory devices, one area playing a significant role in keeping Philips’ head above water is its image-guided therapy segment. read more By Heather Landi Five years in the making, the nation's top health IT agency released Tuesday the Trusted Exchange Framework and Common Agreement, a critical step in establishing a nationwide data-sharing network. read more By Fraiser Kansteiner Problems at Catalent's plant “allegedly” fueled recent supply woes for Novo Nordisk’s obesity drug Wegovy, BioProcess International first reported in early January. For its part, Novo said a contract manufacturer doing syringe filling on the GLP-1 med had temporarily halted deliveries following a manufacturing glitch. read more By Conor Hale XTAL BioStructures was bought in a $6 million all-cash deal. The company includes 18 employees and a headquarters just outside Boston. read more | 